[A22-42] Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Addendum to Commission A21-150
Last updated 20.05.2022
Project no.:
A22-42
Commission:
Commission awarded on 12.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps that cannot be adequately controlled with systemic corticosteroids and/or surgery
After addendum now hint of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-150 | Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20-05-2022 A G-BA decision was published.